Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of FavId (Tumor-Specific Idiotype-KLH) and Soluble GM-CSF Immunotherapy in Patients With Stable or Progressive Grade 1 and 2 Follicular B-Cell Lymphomas

NCT00036426 is registered in ClinicalTrials.gov with Favrille as lead sponsor.

NCT NCT00036426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00036426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of FavId (Tumor-Specific Idiotype-KLH) and Soluble GM-CSF Immunotherapy in Patients With Stable or Progressive Grade 1 and 2 Follicular B-Cell Lymphomas
Lead sponsor
Favrille
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2001
Completion date
Not reported
Enrollment
22
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, low-grade